A388870 Stock Overview
Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pharos iBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,200.00 |
| 52 Week High | ₩25,000.00 |
| 52 Week Low | ₩8,570.00 |
| Beta | 0 |
| 1 Month Change | -13.19% |
| 3 Month Change | 28.70% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 74.11% |
Recent News & Updates
Shareholder Returns
| A388870 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.2% | 2.4% | 0.6% |
| 1Y | n/a | 11.1% | 6.9% |
Return vs Industry: Insufficient data to determine how A388870 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A388870 performed against the KR Market.
Price Volatility
| A388870 volatility | |
|---|---|
| A388870 Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A388870's share price has been volatile over the past 3 months.
Volatility Over Time: A388870's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 30 | n/a | www.pharosibio.com |
Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-protein inhibitor for the treatment of metastatic cancer; PHI-401, an anaplastic lymphoma kinase (ALK) protein inhibitor; and PHI-501 a pan-RAF/DDRs inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Pharos iBio Co., Ltd. Fundamentals Summary
| A388870 fundamental statistics | |
|---|---|
| Market cap | ₩196.37b |
| Earnings (TTM) | -₩8.86b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-22.2x
P/E RatioIs A388870 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A388870 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩11.02m |
| Gross Profit | -₩11.02m |
| Other Expenses | ₩8.85b |
| Earnings | -₩8.86b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -685.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A388870 perform over the long term?
See historical performance and comparison